Mati Therapeutics Inc.

Qlt Inc.

Valeant Pharmaceuticals International

Valery Rubinchik

Alan R Rapacki

Sylvie Sim

Danny Shen

John B Holds

Charles Richard Kjellbotn

Deepank Utkhede

Louise Culham

Suzanne Cadden

Yong Hao

Greg Heacock

Wes A Williams

Philippe Maria Clotaire Margaron

Beth Anne Allison

Russell G Hodge

Charles Richard Kjelbotn

Michael David Leslie Stonefield

Lacrimal implants and related methods providing secure, wedgable retention within a lacrimal punctum and associated canaliculus of an eye are disclosed. The lacrimal implants can comprise an implant body configured for at least partial insertion through the lacrimal punctum and into the canaliculus. The implant body can include first and second portions, and can extend from a proximal end of the first portion defining a longitudinal proximal axis to a distal end of the second portion defining a longitudinal distal axis. The implant body can be configured such that, when implanted using an integral dilator, an angled intersection exists between the proximal and distal axes. In this way, at least a portion of the implant body can be biased against at least a portion of the lacrimal canaliculus located at or more distal to a canalicular curvature, thereby retaining an implanted position of the lacrimal implant using anatomical structures.

Lacrimal implants and related methods

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Lacrimal implants for treating diseases or disorders are disclosed. More particularly, lacrimal implants, methods of making such implants, and methods of treating ocular, respiration, inner ear or other diseases or disorders using such implants are disclosed.

A laser system including: a laser source operable to emit a first laser beam having a first operating wavelength and a second laser beam having a second operating wavelength; a fiber optic cable to guide and homogenize the first and second laser beams; an expander to increase the diameter of the first and second laser beams; a cylinder to guide the first and second laser beams and limit respective diameters of the first and second laser beams, wherein the cylinder is positioned after the expander on an optical path of the laser beam; a first optical system to collimate the first and second laser beams, wherein the optical system is positioned after the cylinder on the optical path of the first and second laser beams; a spot-size selector comprising a plurality of apertures, wherein the spot-size selector is positioned after the first optical system on the optical path of the first and second laser beams; and a second optical system to focus the first and second laser beams on a tissue of the patient.

Photodynamic therapy laser

A laser system including: a laser source operable to emit a first and a second laser beam having first and second operating wavelengths, respectively; a fiber optic cable to guide and homogenize the laser beams; an expander to increase the diameter of the laser beams; a cylinder to guide the laser beams and limit respective diameters of the first and second laser beams, wherein the cylinder is positioned after the expander on an optical path of the laser beam; a first optical system to collimate the laser beams, wherein the optical system is positioned after the cylinder on the optical path of the laser beams; a spot-size selector comprising a plurality of apertures, wherein the spot-size selector is positioned after the first optical system on the optical path of the laser beams; and a second optical system to focus the laser beams on a tissue of the patient.

The present invention relates to the use of low-dose photodynamic therapy (PDT) to prevent, treat, inhibit or reduce restenosis in blood vessels. The present invention may be used in combination with any angioplastic procedure to prevent restenosis or to decrease the intima thickness, and thus luminal narrowing.

Use of low-dose PDT to inhibit restenosis

Growing community of inventors

Richmond, CA, United States of America

Valery Rubinchik